Characteristics of Patients with Hereditary Angioedema Who Reduced Lanadelumab Treatment Administration Frequency: A Retrospective Observational Study of US Claims Data
Abstract Background Lanadelumab is the only long-term prophylaxis indicated for reduced administration frequency in patients with hereditary angioedema who have been well controlled for > 6 months. Understanding the characteristics of patients who reduce administration frequency will help identif...
Saved in:
| Main Authors: | Nicole Princic, Kristin A. Evans, Chintal H. Shah, Krystal Sing, Salomé Juethner, Bob G. Schultz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | https://doi.org/10.1007/s40801-024-00470-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hereditary angioedema plasma proteomics following specific plasma kallikrein inhibition with lanadelumab
by: Dan Sexton, et al.
Published: (2025-05-01) -
Evolution of Treatments for Hereditary Angioedema in Italy: Use of Lanadelumab in Clinical Practice
by: Marta Nugnes, et al.
Published: (2025-06-01) -
A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumab
by: Yanhua Xu, et al.
Published: (2025-08-01) -
Matching-adjusted indirect comparison between garadacimab and lanadelumab for the long-term prophylactic treatment of patients with hereditary angioedema
by: Sarah Walsh, et al.
Published: (2025-07-01) -
One-year real-life outcomes of lanadelumab therapy in Romanian patients with hereditary angioedema due to C1-inhibitor deficiency
by: Noémi Anna Bara, et al.
Published: (2025-08-01)